September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Is intracameral moxifloxacin a safe option for prevention of post cataract endophthalmitis?
Author Affiliations & Notes
  • Nelise de Paiva Lucena
    UFPE, Recife, PE, Brazil
  • Kaline Sandrelli Alves Ferreira
    UFPE, Recife, PE, Brazil
  • Bruna Marília Alves dos Santos
    UFPE, Recife, PE, Brazil
  • Maria Isabel Lynch
    UFPE, Recife, PE, Brazil
  • Rodrigo Pessoa Cavalcanti Lira
    UFPE, Recife, PE, Brazil
    UNICAMP, Campinas, Brazil
  • Footnotes
    Commercial Relationships   Nelise Lucena, None; Kaline Sandrelli Alves Ferreira, None; Bruna Marília dos Santos, None; Maria Isabel Lynch, None; Rodrigo Lira, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5403. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nelise de Paiva Lucena, Kaline Sandrelli Alves Ferreira, Bruna Marília Alves dos Santos, Maria Isabel Lynch, Rodrigo Pessoa Cavalcanti Lira; Is intracameral moxifloxacin a safe option for prevention of post cataract endophthalmitis?. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5403.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intracameral moxifloxacin (MFLX) have been used worldwide as an off-label option for prevention of post cataract endophthalmitis. There are some concerns related to long-term safety. The purpose of this research was to study the 2-years safety of intracameral MFLX.

Methods : A retrospective survey included the last 100 surgeries before (control group) and the first 100 surgeries after the introduction of intracameral MFLX for prevention of post cataract endophthalmitis (MFLX group) at our hospital in April 2013 (200 eyes of 200 patients). The inclusion criteria were: patients with indication of cataract surgery, ≥ 60 years old, and without history of allergy to quinolones. It was excluded patients with any other ocular disease than cataract (glaucoma, retinal disease, trauma, cornea dystrophy, etc.). The same surgeon performed all surgeries. The operative technique was phacoemulsification (Infiniti®, Alcon®) with intraocular lens implantation (Sensar® AR40e, Abbott®). The MFLX group received moxifloxacin (150-μg/0.03 ml) at the end of the surgery. The records of 2-years follow up were reviewed. The main outcomes were (preoperative and 2-years follow up) corneal endothelial cell density (EM935®, Haag-Streit®), corneal pachymetry (Ocuscan®, Alcon®), best-corrected visual acuity and intraocular pressure. Written consent was obtained from each patient. The institutional research ethics committee approved the study. Between-group differences for two groups continuous variables were compared using the Mann-Whitney U-test. Gender was compared using the Chi-square test.

Results : There was no statistical difference between groups in gender distribution, mean age, corneal endothelial cell density, corneal pachymetry, best-corrected visual acuity and intraocular pressure (Table 1). No adverse events or endophthalmitis were observed.

Conclusions : The results suggest MFLX is a safe option for prevention of post cataract endophthalmitis.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×